Results 1 to 10 of about 12,072 (205)
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. [PDF]
Expert Opin Drug Metab Toxicol, 2021 Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes. This systematic review summarizes the available evidence for all biomarkers proposed to have a role in the diagnosis or prognosis of DILI.
Atallah E +6 more
europepmc +9 more sources
Clinical management of patients with drug-induced liver injury (DILI). [PDF]
United European Gastroenterol J, 2021 AbstractDrug‐induced liver injury (DILI) should be considered in all patients with recent elevation of liver tests without obvious etiology and normal hepatobiliary imaging. There is currently no biomarker that is helpful in diagnosis which relies on clinical and laboratory findings.
Björnsson ES.
europepmc +4 more sources
Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. [PDF]
Arch Toxicol, 2021 AbstractDrug-induced liver injury (DILI) is an adverse toxic hepatic clinical reaction associated to the administration of a drug that can occur both at early clinical stages of drug development, as well after normal clinical usage of approved drugs. Because of its unpredictability and clinical relevance, it is of medical concern. Three DILI phenotypes
Quintás G +5 more
europepmc +7 more sources
Drug-induced liver injury (DILI) - mechanisms and diagnostic [PDF]
Farmacja Polska, 2022 The drug-induced liver injury (DILI) is one of the leading causes of the liver disease in developed countries. These injuries may be the result of constant drug hepatotoxicity or idiosyncrasy associated with the drug or its metabolite.
Marta Małysz +3 more
doaj +2 more sources
When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network. [PDF]
Am J Gastroenterol, 2023 INTRODUCTION: Diagnosis of drug-induced liver injury (DILI) is difficult. We reviewed cases in the DILI Network prospective study that were adjudicated to have liver injury due to other causes to discover pearls for improved diagnostic accuracy.
Barritt AS +6 more
europepmc +3 more sources
Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. [PDF]
Ann Transl Med, 2021 Clinical features of idiosyncratic drug induced liver injury (DILI) are well described in cases that have been assessed for causality using the Roussel Uclaf Causality Assessment Method (RUCAM), but our understanding of the mechanistic steps leading to injury is fragmentary.
Teschke R, Uetrecht J.
europepmc +4 more sources
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment. [PDF]
Metabolites, 2022 Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry.
Moreno-Torres M, Quintás G, Castell JV.
europepmc +6 more sources
Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report. [PDF]
Cureus, 2022 Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI).
Zachou M +4 more
europepmc +3 more sources
Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI). [PDF]
Mol Pharm, 2020 Drug-induced liver injury (DILI) is one the most unpredictable adverse reactions to xenobiotics in humans and the leading cause of postmarketing withdrawals of approved drugs. To date, these drugs have been collated by the FDA to form the DILIRank database, which classifies DILI severity and potential.
Minerali E +4 more
europepmc +4 more sources
A Rare Case of Drug-Induced Liver Injury (DILI) From Topiramate. [PDF]
CureusA 72-year-old male individual with a past medical history of seizures and ongoing management with topiramate for two months presented at the emergency department with jaundice. Ten days before the presentation, the patient started feeling fatigued and had intermittent generalized mild pain (grade 3/10) with dark-brown discoloration of urine.
Macasaet R +5 more
europepmc +3 more sources